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Background: Many studies have demonstrated that chemoradiotherapy followed by surgery (CRTS) prolongs the
5-year survival rate of resectable esophageal carcinoma patients. However, the effect of CRTS on postoperative
complications, local recurrence and distant metastasis remains controversial. We performed a systematic review of
the literature and conducted a meta-analysis to assess the postoperative efficacy of CRTS compared with surgery
alone (SA).
Methods: Pubmed, Web of Science and the Cochrane library Databases were used to identify published studies
between 2000 and 2013 that directly compared CRTS with SA. The pooled relative risk (RR) and its corresponding
95% confidence interval (95% CI) constituted the principal measure of treatment effects. Heterogeneity was
assessed by the χ2 and I2 statistic.
Results: The final analysis included 1930 resectable esophageal carcinoma cases from 13 randomized controlled trials
(RCTs). Compared with SA, CRTS was associated with significantly decreased postoperative mortality, local recurrence
and distant metastasis rates, with RR (95% CI) = 0.64 (0.49–0.84), 0.53 (0.39–0.73), 0.82 (0.68–0.98); p = 0.001, <0.00001,
=0.03, respectively. However, there was no significant difference in postoperative complication incidence between the
two groups (RR, 1.09; 95% CI, 0.96–1.24; p = 0.18).
Conclusions: CRTS significantly decreased postoperative mortality, local recurrence and distant metastasis rates
compared to SA. Additionally, there were no increased postoperative complications for patients with resectable
esophageal carcinoma.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1531519216130950
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Esophageal cancer is a significant health problem world-
wide. There are approximately 482,300 new cases of
esophageal cancer and 406, 800 deaths annually [1].
Esophagectomy is considered the gold standard treat-
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unless otherwise stated.However, the prognosis for patients treated with surgery
alone (SA) remains poor [2]. In addition to advances in
supportive care, improved and standardized surgical
techniques have also contributed to an increase in the
rate of curative resection [3]. Despite changes in man-
agement over the past 20 years, SA leads to relatively
few long-term survivors [4]. Thus, there is interest in
using combinations of chemoradiotherapy and local sur-
gical treatment due to the high rates of locoregional and
distant failure. Many studies have investigated the effect
of chemoradiotherapy followed by surgery (CRTS) on
the postoperative survival rate and quality of life.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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increases the rate of complete resection [5], particularly for
patients with locally advanced disease. Many randomized
controlled trials (RCTs) have generated promising results
with respect to 5-year survival rates. The evidence support-
ing the survival benefits of CRTS is clear for both esopha-
geal squamous-cell carcinoma (SCC) and adenocarcinoma
(AC) histology compared with SA. Clinicians agree there is
a survival advantage associated with the CRTS regimen.
However, there are different opinions on the impact of
postoperative treatment effects [6,7]. There is a persistent
concern that neoadjuvant treatment may cause an undesir-
able increase in postoperative complications.
The published meta-analyses have also failed to reach a
consensus on postoperative efficacy [8-10]. Therefore, we
performed a meta-analysis of prospective RCTs to exam-
ine resectable esophageal carcinoma patients treated with
CRTS or SA. We compared the postoperative complica-
tions, local recurrence and distant metastasis associated
with the two treatment regimens. The results of this study
provide valuable evidence for clinical decision-making.
Methods
Identification of relevant studies
We searched PubMed, Web of Science and the Cochrane
library databases to retrieve related studies published be-
tween 2000 and 2013. The search terms included “neoad-
juvant therapy”, “chemoradiotherapy followed by surgery”,
“chemoradiotherapy”, “surgery or operation or esophagec-
tomy”, “esophagus or esophageal cancer or carcinoma”.
To Manual searches of reference lists were also performed
to ensure that no studies were missed.
Inclusion criteria
The search results met the following inclusion criteria:(1)
the study was a prospective RCT designed to compare
CRTS with SA treatment of resectable esophageal cancer;
(2) the assessment of the liver, kidney, heart, lung, etc. for
the included patients have confirmed them to be fit for
surgery; (3) the study clearly described the diagnoses and
the sources of the cases and controls, the sample size, risk
ratio (RR) and their 95% confidence interval (CI), or data
that would allow those findings to be inferred; (4) clear
follow-up censored survival, complications, number of
cases for local recurrence and metastasis, and follow-up
rate of > 95% in the original study.
Data extraction and quality assessment
Two investigators (Deng, Wang) independently reviewed
titles and abstracts of all citations identified by the litera-
ture search. The data were extracted by the one author.
Any discrepancies were resolved by discussion among all
authors, and consensus was reached. For each study, the
following data were extracted: the first author of thestudy, the year of publication, the author’s country, the
treatment regimen, tumor histology, patient outcomes
including postoperative mortality, complications, recur-
rence and distant metastasis.
The trial validity assessment was conducted in depend-
ently and in duplicate. A trial quality score was assigned
using three aspects: blinding, randomization and handling
of withdrawals and dropouts. These aspects were assessed
using a scale of 1–5, according to methods previously de-
scribed by Jadad et al [11].
Statistical analysis
The analysis was performed using Review Manager Ver-
sion 5.2 software and Stata Version 12.0 software. To com-
bine results from individual trials, we used the proportion
of events observed in CRTS and SA groups. The RR with
the corresponding 95% CI was calculated for each trial
using the observed proportions of events. All patient data
were analyzed according to intention-to-treat principles.
The overall RR was tested for significance using a Mantel-
Haenszel χ2 test. The outcome variables were the treat-
ment RR of the postoperative mortality, complications,
local recurrence and distant metastasis rates between
CRTS and SA groups. The statistical significance of the
summary RR was determined with a Z-test, and p < 0.05
was considered statistically significant. Subgroups of pa-
tients were assigned based on ethnicity and histology, and
the groups were used to compare the impact on postoper-
ative treatment outcomes.
Evaluation of heterogeneity and publication bias
The heterogeneity assumption was evaluated with a
chisquare-based Q-test. A p value ≥ 0.10 for the Q-test in-
dicated a lack of heterogeneity among studies. We used a
fixed effects model to calculate the total RR and 95% CI,
or used a random effects model. If p < 0.1 and I2 > 50%,
the heterogeneity was regarded as statistically significant.
Egger’s test was performed to assess whether there was
any publication bias due to the literature evaluated.
Results
Characteristics of eligible studies
We initially identified 384 relevant studies in the litera-
ture: 75 preliminary studies were included after reading
the title and study summary, and 62 studies excluded
after reading the full text (45 did not meet the standard
of enrolled patients, 15 non-randomized controlled tri-
als, 2 unpublished full-text articles). Thus, there were 13
RCTs that meet our inclusion criteria [12-24]. The flow
chart of the meta-analysis is shown in Figure 1. There
were a total of 1930 patients within these 13 RCTs.
There were 970 patients in the CRTS group and 960 pa-
tients treated with SA. The selected study characteristics
are summarized in Table 1.
Figure 1 Flow chart of the meta-analysis.
Deng et al. Diagnostic Pathology 2014, 9:151 Page 3 of 8
http://www.diagnosticpathology.org/content/9/1/151Mortality and complications after surgery
The number of actual surgeries was analyzed. There was a
statistically significant difference in the postoperative mor-
tality of patients treated with CRTS compared to SA; the
RR (95% CI) = 0.64 (0.49–0.84), p = 0.001. However, there
was no statistical significance detected in postoperative
complications; RR (95% CI) =1.09 (0.96–1.24), p = 0.18.
All the results of the statistical analysis are shown in
Table 2. The forest plots are shown in Figure 2.
To examine the possible effect of ethnicity on postoper-
ative mortality and complications, we also conducted sub-
group analyses to evaluate whether patients from the
West (e.g., Europe, USA) or the East (e.g., Asia) had differ-
ent treatment outcomes following CRTS or SA. This sub-
group analysis showed that the participant’s location had
an impact on postoperative mortality for CRTS relative
to SA. The RR for postoperative mortality was 0.56 (95%
CI = 0.42–0.75, p < 0.0001) for the East and 0.83 (95%
CI = 0.47–1.46, p = 0.52) for the West. However, the RR
for postoperative complications was 1.23 (95% CI = 0.96–
1.56, p = 0.10) for the East and 1 (95% CI =0.87–1.15,
p = 0.98) for the West. These values were not significantly
increased by CRTS (Table 3).
A subgroup analysis by histological type for postopera-
tive mortality where histology data were available yieldedan RR for SCC of 0.54 (95% CI 0.42–0.68; p < 0.0001),
in favor of CRTS. For AC, the RR was 1.26 (0.76–2.06;
p = 0.37). There was a significant survival benefit for
SCC, but not for AC (Table 3).
Effect on recurrence and metastasis
Eight RCTs provided related data on tumor recurrence
and metastasis. The patients treated with CRTS had
markedly lower incidences of local recurrence (RR: 0.53,
95% CI: (0.39–0.73), p < 0.00001) and distant metastases
(RR: 0.82, 95% CI: (0.68–0.98), p = 0.03) (Figure 3).
A subgroup analysis based on ethnicity showed that race
had an impact on postoperative local recurrence and dis-
tant metastasis for CRTS relative to SA. The RR for post-
operative local recurrence was 0.52 (95% CI = 0.33–0.84,
p = 0.008) for the East and 0.51 (95% CI = 0.34–0.76,
p = 0.001) for the West. The RR for distant metastasis for
the East was 0.62 (95% CI = 0.44–0.88, p = 0.007), which
was significantly increased by CRTS. However, the RR for
the West was 0.93 (95% CI = 0.75–1.16, p = 0.10), which
was not significantly increased by CRTS (Table 3).
Sensitivity analysis and publication bias
The sensitivity analysis did not exclude any studies
because none of the studies could alter the overall
Table 1 Characteristics of 13 RCTs included in the final meta-analysis
First author Year Country Sample size Pathology Neoadjuvant treatment schedule Jadad score
CRTS SA
Urba [12] 2001 USA 50 50 SCC (25%); AC (75%) 45 Gy; 1.5 Gy per fraction over 3 weeks 2
Two cycles: cisplatin 20 mg/m2 days 1–5;
fluorouracil 300 mg/m2 days 1–21; vinblastine
1 mg/m2 days 1–4
An [13] 2003 China 48 49 SCC 36 Gy, 1.2 Gy per fraction over 17 days 3
First cycle: 5-fluorouracil 1 mg/m2, 5–6 hours,
days 1–5; cisplatin 25 mg/m2.
Second cycle: 5-fluorouracil 0.5 g/m2, days
21–25; cisplatin 25 mg/m2, days 22–25
Lee [14] 2004 Korea 51 50 SCC 45.6 Gy, 1.2 Gy per fraction over 28 day 2
Two cycles: cisplatin 60 mg/m2 days 1;
fluorouracil 1000 mg/m2 days 3–5
Burmeister [15] 2005 Australia 128 128 SCC (37%); AC (62%) 35 Gy in 15 fractions over 3 weeks 3
One cycles: cisplatin 80 mg/m2 days 1;
fluorouracil 800 mg/m2 days 1–4
Natsugoe [16] 2006 Japan 22 23 SCC 40 Gy, 2 Gy per fraction over 4 weeks 2
cisplatin 7 mg over 2 hours; 5-fluorouracil
350 mg over 24 hours
Tepper [17] 2008 USA 30 26 SCC (25%); AC (75%) 50.4 Gy, 1.8 Gy per fraction over 5.6 weeks 3
Two cycles: cisplatin 100 mg/m2 days 1;
fluorouracil 1000 mg/m2 per day days 1–4
Cao [18] 2009 China 118 118 SCC 40 Gy, 2 Gy per fraction over 4 weeks 2
cisplatin 20 mg/m2 per day days 1–5;
fluorouracil 500 mg/m2 per day days 1–5;
mitomycin 10 mg/m2 per day day 1
Hurmuzlu [19] 2010 Norway 62 45 SCC (36%); AC (64%) 66 Gy, 2 Gy per fraction over 6.5 weeks 3
Three cycles: cisplatin 100 mg/m2 days 1;
fluorouracil 1000 mg/m2 per day days 1–5
Lv [20] 2010 China 80 80 SCC 40 Gy, 2 Gy per fraction over 4 weeks 2
Two cycles: cisplatin 20 mg/m2 per day,
days 1–3, 22–25;
paclitaxel 135 mg/m2
Saeki [24] 2011 Japan 76 92 SCC 30-42 Gy , 1.8 Gy per fraction 3
cisplatin: 5 mg/m2/day, 5-FU: 250 mg/m2/day,
administered on weekdays, repeated every
3-4 weeks
van Hagen [21] 2012 Netherlands 168 186 SCC (23%); AC (75%) 41.4 Gy, 1.8 Gy per fraction over 4.6 weeks 2
5 weeks chemotherapy: carboplatin area under
curve =2 , paclitaxel 50 mg/m2 on day 1 weekly
Fujiwara [22] 2013 Japan 52 36 SCC 40 Gy, 2 Gy per fraction over 4 weeks 3
5-FU (500 mg/m2/day), CDDP (15-20 mg/day),
days 1-5, repeated every 3 weeks
Smit [23] 2013 Italy 75 75 SCC 41.4 Gy,1.8 Gy per fraction over 4.6 weeks 3
5 weeks: paclitaxel (50 mg/m2), carboplatin
(area under the curve = 2)
CRTS: chemoradiotherapy followed by surgery SA: surgery alone SCC: squamous cell carcinoma AC: adenocarcinoma.
Deng et al. Diagnostic Pathology 2014, 9:151 Page 4 of 8
http://www.diagnosticpathology.org/content/9/1/151estimates for postoperative mortality, postoperative com-
plications, postoperative local recurrence and postopera-
tive distant metastasis. The Q-test of heterogeneityshowed that these analyses had a p ≥0.10 (Table 2),
which suggests that neither analyses demonstrated het-
erogeneity among the included RCTs. We then selected
Table 2 Meta-analysis for the outcomes of CRTS versus SA




CRTS SA F RR (95% CI) P
Postoperative mortality 7 492 545 F 0.64 [0.49, 0.84] 0.001 0.83 0.040
Postoperative complication 10 586 641 F 1.09 [0.96, 1.24] 0.18 0.75 0.752
Local recurrence 8 484 481 F 0.51 [0.38, 0.70] <0.0001 0.32 0.386
Postoperative metastasis 8 484 481 F 0.82 [0.68, 0.98] 0.03 0.25 0.016
CRTS: chemoradiotherapy followed by surgery SA: surgery alone.
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analysis.
The p values based on Egger’s test for postoperative
mortality, complications, local recurrence and distant
metastasis are shown in Table 2. The results showed that
no publication bias existed for postoperative complica-
tions and local recurrence (p = 0.752, 0.386, respectively).
However, publication bias existed for postoperative mor-
tality and distant metastasis (p = 0.04, 0.01, respectively).
Therefore, these results need to be further examined in
additional studies.
Discussion
Previous studies have demonstrated that CRTS significantly
improves the long-term survival rate of esophageal cancer
compared with SA alone [25]. Consistent with this result,Figure 2 The forest plots of postoperative mortality and complication
surgery alone (SA) using a fixed effects model.many RCTs and Meta studies have reached a consensus.
We emphasized the investigation of neoadjuvant chemora-
diotherapy in the present meta-analysis due to persistent
anxiety that neoadjuvant chemoradiotherapy has a negative
impact on postoperative treatment effects.
The results of our meta-analysis showed there was a
statistically significant advantage for postoperative mor-
tality, local recurrence and distant metastasis of esopha-
geal cancer patients treated with CRTS compared with
SA (p < 0.05). This finding is interestingwith respect to a
recently updated meta-analysis performed by Sjoquist et
al [10] published in Lancet Oncology. The study included
12 RCTs with 1854 cases and had strict inclusion criteria
and rigorous statistical analysis. The HR for all-cause
mortality for neoadjuvant chemoradiotherapy was 0.78
(95% CI 0.70-0.88; p < 0.0001). The updated meta-analysisof chemoradiotherapy followed by surgery (CRTS) versus
Table 3 Subgroup analysis of the postoperative treatment outcomes
Subgroup Category Included studies Sample size Test for overall effect
CRTS SA RR (95% CI) P
Postoperative mortality based on ethnicity The West 5 377 417 0.83 [0.47, 1.46] 0.52
The East 2 115 128 0.56 [0.42, 0.75] <0.0001
Postoperative complication based on ethnicity The West 4 209 231 1.00 [0.87, 1.15] 0.98
The East 5 357 387 1.23 [0.96, 1.56] 0.10
Local recurrence based on ethnicity The West 4 283 279 0.51 [0.34, 0.76] 0.001
The East 4 201 202 0.52 [0.33, 0.84] 0.008
Postoperative metastasis based on ethnicity The West 4 283 279 0.93 [0.75, 1.16] 0.53
The East 4 201 202 0.62 [0.44, 0.88] 0.007
Postoperative mortality based on histology SCC 7 231 247 0.54 [0.42, 0.68] <0.0001
AC 5 295 313 1.26 [0.76, 2.06] 0.37
SCC: squamous cell carcinoma AC: adenocarcinoma.
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benefit of CRTS in decreasing postoperative mortality
compared with SA. The survival benefits for neoadjuvant
chemoradiotherapy were similar for squamous-cell carcin-
oma (HR 0.8, 95% CI 0.68-0.93; p = 0.004) and adenocar-
cinoma (HR 0.75, 0.59-0.95; p = 0.02) subgroups. The
survival benefit for SCC was consistent with our subgroup
analysis for SCC (RR 0.54, 95% CI 0.42–0.68; p < 0.0001).
There was a smaller benefit associated with AC in our
analysis, but it was not statistically significant (RR 1.26,
95% CI 0.76–2.06; p = 0.37).Figure 3 The forest plots of postoperative local recurrence and distan
(CRTS) versus surgery alone (SA) using a fixed effects model.In a meta-analysis conducted by K. Kumagai1 et al
[26], neoadjuvant chemoradiotherapy patients with SCC
were associated with a significantly higher risk of post-
operative mortality (RR 1.95, 1.06 - 3.60; p = 0.032) com-
pared with SA. However, there was no difference among
patients with AC or in the esophageal cancer group
overall. The reason for this finding may be that most
of the included trials were conducted in the 1980s. After
excluding trials conducted in the 1980s, the results
revealed the difference was not statistically significant
compared with surgery alone in the SCC subgroup.t metastasis rates of chemoradiotherapy followed by surgery
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recurrence and distant metastasis. The two indictors were
rarely published in previous meta-analyses. Compared
with SA, CRTS significantly decreased the local recur-
rence and distant metastasis rates of the tumor (p < 0.05).
This finding may contribute to better survival outcomes
and lower postoperative mortality. There was evidence
that patients treated with SA were more likely to undergo
the scheduled surgery. However, the rate of complete
resection in the CRTS group was higher than in the
SA group [27]. In theory, neoadjuvant chemoradiotherapy
might lead to downstaging of the primary tumor and
have positive effects on mediastinal nodes. This may ac-
count for the lower local recurrence rate. In this study,
no subgroup analysis of postoperative complications,
local recurrence or distant metastasis based on histology
was investigated because the exact number of patients
with these complications was not reported separately
for SCC and AC.
We screened 13 RCTs based on different databases
from the period of 2000 to 2013 with a larger sample
size and a wider distribution range than used in previous
studies. This difference is the strength of our study com-
pared to other previous meta-analyses that included
studies mostly published in 1990s. The use of radiation
has developed rapidly in the past 20 years. Thus, the role
of chemoradiotherapy in multimodality therapy has be-
come more important. A systematic analysis using the
latest research data is expected to produce more accur-
ate results.
The management of esophageal cancer with neoadju-
vant strategies is complex, and the available evidence is
conflicting. We have discussed some of these controver-
sies and attempted to resolve them within the context of a
well-designed randomized controlled trial. We have made
initial recommendations for the trial design, but this re-
mains open for discussion and scrutiny. The meta-analysis
in this study has the following limitations: some eligible
studies may be missing although our big effort; the current
study did lack the accurate number of patients who suf-
fered with postoperative complication, local recurrence
and distant metastasis with SCC and AC, respectively.
Publication bias existed in postoperative mortality and
distant metastasis, which may attribute to less studies in-
cluded. It seems to us that the conclusions should be
interpreted with caution. A larger number studies will be
needed to verify our results further.
There is no consensus for the treatment of esophageal
carcinoma and standard treatment regimens. However,
most clinical studies show that preoperative chemora-
diotherapy combined with surgery is a triple therapy
model that may improve the clinical efficiency and the
long-term survival rate. Thus, this strategy may become
the standard treatment regimen [28]. A meta-analysisby Cavallin [29] revealed that patients with excellent
histopathological responses benefit from neoadjuvant
regimens. However, patients with poor histopathological
responses have no benefit and have worse prognoses.
Therefore, predictive markers to allow for individualization
of multimodality treatment in locally advanced esophageal
cancer are urgently needed. There was evidence that
ATP-binding cassette sub-family G member 2 (ABCG2)
and Vacuolar-H + -ATPase (V-ATPase) were associated
with pathological grade, TNM stage and tumor metastasis
in esophageal squamous cancer cells [30]. Furthermore,
HER2 overexpression was associated with gastroesopha-
geal junction (GEJ) site, intestinal cancer subtype, and
well or moderately differentiated carcinomas [31]. All
these markers are associated with clinicopathological fea-
tures for esophageal carcinoma and contribute to optimize
treatment regimen.
Conclusions
CRTS significantly reduced postoperative mortality, local
recurrence and distant metastasis rates compared to SA.
However, CRTS did not increase the postoperative com-
plication incidence compared with SA.
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